Juq-470 May 2026

Compute & AI: Onboard neural inference cluster for real-time sensor fusion, target classification, and path planning. Dual-mode autonomy — supervised autonomy for remote operators and emergent autonomy for denied-comm scenarios.

Communications: Burst encrypted uplink (directional, frequency-hopping) plus low-probability-of-intercept (LPI) beacon mode. Local mesh capability to act as a node among other JUQ units.

Survivability: Redundant critical systems, controlled self-burial sequence for anti-tamper, and a selective EM shielding matrix.

CMC and formulation

First-in-human (FIH) clinical plan

Biomarker strategy

Regulatory & IP

Commercial & competitive analysis

| Issue | Evidence / Rationale | Mitigation strategies | |-------|----------------------|-----------------------| | Hypertension | Common class effect of VEGFR inhibition; observed in ≥30 % of patients in early trials (mostly grade 1–2). | Routine BP monitoring; antihypertensive therapy (ACE inhibitors or calcium‑channel blockers). | | Hyperphosphatemia | FGFR inhibition can reduce renal phosphate excretion. | Phosphate binders, dietary counseling, regular serum phosphate checks. | | Gastrointestinal toxicity | Nausea, diarrhea reported in pre‑clinical high‑dose studies. | Prophylactic anti‑emetics; dose adjustments if ≥ grade 3. | | Hepatic enzyme elevation | ALT/AST elevations at higher doses in rats; limited human data so far. | Baseline and periodic LFTs; hold or reduce dose if >3× ULN. | | Potential drug–drug interactions | Metabolized primarily by CYP3A4 (based on in‑vitro microsome assays). | Avoid strong CYP3A4 inducers/inhibitors; consider dose modifications. | JUQ-470